# Jiangsu Aidea Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-aidea-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Yangzhou, China
- Website: aidea.com.cn
- Total disclosed funding: $28M
- Latest round: Series B (Apr 24, 2017)
- Investors on record: 7

## About

Based in Yangzhou, China and established in 2009, Jiangsu Aidea Pharmaceutical Co., Ltd. operates as a pharmaceutical company which focuses on antitumor, antivirus and cardiovascular areas. The company has set up a branch office in Nanjing. It has been recognized as a National High-Tech Enterprise. In April 2017, the company raised RMB CNY million in series B funding from new investors GLB Capital, Jiangsu Longrich Bio-Science and Shanghai Peisheng Enterprise Management Consulting Center as well as returning investor Huatai Zijin Investment. In 2020, Aidea Pharmaceutical was listed on the Shanghai Stock Exchange.

Based on the protein drug R&D platform and chemical drug R&D platform, the company focuses on drug R&D in three major fields which are antitumor, antivirus and cardiovascular. With its self-developed on-line adsorption technology for human proteins, the company has developed products involving human urokinase and high-purity human albumin.

The company's revenue and net income for 2022 were CNY 244.22 million and CNY -124.2 million, respectively.

## Funding rounds

- Series B, Apr 24, 2017, $23M — Jiangsu Longrich Bio-Science, Huatai Zijin Investment, GLB Capital, Shanghai Peisheng Enterprise Management Consulting Center
- Series A, Oct 9, 2015, $4.7M — Huatai Securities, Starr International Company, Addor Capital, Huatai Zijin Investment

## Investors

- Huatai Securities — Series A
- Starr International Company — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series A, Series B
- Jiangsu Longrich Bio-Science — Series B
- GLB Capital — Series B
- Shanghai Peisheng Enterprise Management Consulting Center — Series B